Join
Live feed
·
INSIDERFilingvia Quantisnow
Alnylam Pharmaceuticals Inc. logo

CSO & EVP, Head of Research Fitzgerald Kevin Joseph sold $417,685 worth of shares (1,291 units at $323.54), decreasing direct ownership by 6% to 20,569 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
ALNY· Alnylam Pharmaceuticals Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALNY (Alnylam Pharmaceuticals Inc.) and more on Quantisnow.